Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E39 Peptide Vaccine in Ovarian and Endometrial Cancer
NCT01580696Phase 2Completed
- Start
- Apr 2012
- Primary completion
- Jul 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of folate binding protein E39 in ovarian cancer, endometrial cancer (EC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC). Started Apr 2012; status: completed.
02
Drugs
folate binding protein E39
03
Conditions
ovarian cancerendometrial cancer (EC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01580696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01580696.